


## From the Structure and Function of the Ribosome to new Antibiotics




#### Crick's central dogma of molecular biology: DNA makes DNA makes RNA makes protein






Jim Watson, 1964

## Structural Components of the Ribosome from *E. coli*




Ribosome is 2/3 RNA by mass and is 1/4 bacterial cell mass







J.A. Lake, 1976 (J.M.B. 105, 131)



Joachim Frank, Current Opinion in Strucural Biology (1997).

Nenad Ban, 1995-2000









Poul Nissen, 1997-2000

Seeding and reverse extraction procedures yielded more isometric and reproducible crystals with excellent diffraction properties.






#### Heavy atom cluster derivatives



PIP 314 e-







Ta<sub>6</sub>Br <sup>2+</sup><sub>12</sub> 858 e-





W-11 ~1250 e-



#### **Experimental Electron Density Maps of 50S** 20 A 9 A Frank, Ban, et al 1996 1998 2.4 A 5 A Ban, et al Ban, et al 2000 1999








Nissen, et al. Science (2000)

Many ribosomal proteins have extended, basic regions L39e that penetrate into the interior of the 23S rRNA L44e L19 Ban et al., Science (2000)



# Crick recognized early that the ribosome should be a ribozyme



- "It is tempting to wonder if the primitive ribosome could have been made entirely of RNA"
- F. H. C. Crick, JMB, 38, 367-379 (1968)

The large ribosomal subunit from *H. marismortui*June 2000, 2.4 A resolution

Proteins come no closer than 18 A to the active site



Nissen, et al. Science (2000)

## THE RIBOSOME

## IS

## A RIBOZYME

What is the source

of the

ribosome's catalytic


power


in peptide synthesis?


Martin Schmeing and Jeff Hansen




#### **Peptidyl Transferase Reaction**







#### The pre-reaction ground state



Schmeing, et al, Nature (2005)


### Mutation of A2486 (2451) does not affect the rate of peptide bond formation when the A-site substrate is aminoacyl-tRNA

E.M. Youngman, J.L. Brunelle, A.B. Kochaniak, and Rachel Green, Cell 117, 589-99 (2004)

# Removal of the 2'OH of the P-site A76 reduces the peptidyl-transferase rate by more than 10,000 fold.

J.S. Weinger, K.M. Parnell, S. Dorner, R.Green, and Scott Strobel, Nature Struct Mol Biol 330,11,1101-6(2004)


A possible role for 2' OH on A76 of the P-site in chemical catalysis




Dorner S, Polacek N, Schulmeister U, Panuschka C, Barta A. "Molecular aspects of the ribosomal peptidyl transferase." Biochem Soc Trans. 2002 Nov;30(Pt 6):1131-6.

## Is the transition state being stabilized?

#### The oxyanion of the transition state points away from A2486



#### The oxyanion hole is a water molecule



# Contributors to the ribosome's catalytic power

• Substrate orientation by the 23S rRNA

• Proton shuttle from alpha-amino to the 3'OH by the 2'OH of A76 of the peptidyl-tRNA

• Transition state stabilization by a water molecule bound to the oxyanion of the intermediate

### The Peptidyl Transferase Reaction

Martin Schmeing T. Steitz lab

### National Report

The New Hork Times

#### Lethal Bacterial Infections Are Found More Common

Study Links 19,000 Deaths to Germ in 2005

#### By KEVIN SACK

ATLANTA, Oct. 16 — Nearly 19,000 people died in the United States in 2005 after being infected with virulent drug-resistant bacteria that have spread rampantly through hospitals and nursing homes, according to the most thorough study of the disease's prevalence ever conducted.

vasive MRSA infections by 60 percent after it began screening all patients in 2005.


"This study puts more onus on organizations that don't do active surveillance to demonstrate that they're reducing their MRSA infections," Dr. Peterson said. "Other things can work, but nothing else has been demonstrated to have this kind of impact


An estimate that fatalities could exceed those for AIDS.

Gross sales of antibiotics amount to about \$30 billion per year worldwide. About half target the ribosome, mostly the large subunit.




## 15- and 16-member macrolides bind in the tunnel of the 50S subunit





# Mutation of A2058 to G in E. coli reduces the binding constant for erythromycin by 10,000 fold


Since E. coli A2058 is G2099 in the H. marismortui 50S subunit, many MLSK antibiotics do not bind to this archeal subunit.




G2099 is A2058 in E. coli

# G2099 (A2058 E. coli) was mutated to A2099 in one of the three 23S rRNA genes

Daqi Tu, Gregor Blaha, Peter Moore & Tom Steitz, Cell, 2005.





G2099A Mutation Increases Erythromycin Afinity >10,000 Fold 100% G2099 33% G2099A



~ 3 mM erythromycin

0.003 mM erythromycin






The structures of the antibiotic complexes with the H. marismortui large subunit are being used by Rib-X Pharmaceuticals to design new antibiotics effective against resistant strains.

#### Genesis of $R\chi$ -01 Family of

Compounds



SOMBOUNAS
Bridge- Element NH
F
T1A  T2A  F  NH  NH  NH  NH  NH  NH  NH  NH  NH
T2B NH

	Linezolid	Sparsomycin	T1A	T2A	T2B	T3A	Т3В
<i>E. coli</i> Translation	Intrinsic Affinity						
$IC_{50}(\mu M)$	4.6	≤0.02	0.26	0.03	16	0.03	0.58
Selectivity	Y	N	N	N	Y	N	Y
	MIC (μg/ml)						
S. pneumoniae 02J1175	2	2	4	1	8	≤0.25	0.5
S. pyogenes Msr610	1	2	4	1	4	≤0.25	0.5
E. faecalis P5 (lin <sup>R</sup> )	32	>128	>128	32	128	16	16
H. Influenzae RD1	16	8	>128	>128	>128	>128	>128

### Iterative Cycle Yields Compounds to Treat Respiratory Tract Infections

	Inhibition of Translation (μM)		MIC (μg/ml)		
Compound	Prokaryote	Eukaryote	S. pneumoniae	H. influenzae	
RX-A <sub>1</sub>	0.92	0.23	1	>128	
RX-A <sub>2</sub>	14.6	>200	8	>128	
RX-A <sub>7</sub>	<0.2	1.5	0.25	>128	
RX-A <sub>8</sub>	6.8	>100	0.5	>128	
RX-A <sub>84</sub>	0.083	>100	0.25	2	
RX-A <sub>89</sub>	0.049	>100	0.25	16	
RX-A <sub>188</sub>	<0.02	1.01	0.06	2	
RX-A <sub>258</sub>	<0.02	20	0.25	2	

Rib - X Pharmaceuticals, Inc.


### Superior compounds obtained

	MIC (μg/mL); Target ≤4		
Bacterial Strains	Zithromax	RX-A	RX-B
Streptococcus pneumoniae:			
Point mutation in 23S delivering macrolide resistance	>128	≤0.25	≤0.25
Methylase of 23S + ribosomal protein mutation with resistance to macrolides	>128	≤0.25	1
Acquired efflux pump delivering 14,15- membered macrolide resistance	16	≤0.25	≤0.25
Streptococcus pyogenes:	>128		
Methylase of 23S delivering macrolide resistance		≤0.25	≤0.25
Haemophilus influenzae:			
Tough clinical strain	1	4	4
Enterococcus faecalis:			
Point mutation in 23S delivering linezolid resistance	4	2	≤0.25
Vancomycin & linezolid resistance	>128	1	≤0.25
Vancomycin resistance	>128	≤0.25	≤0.25

### Radezolid: Antimicrobial Activity Against Zyvox-Resistant Enterococci

	MIC (μg/ml)			
Isolate	Radezolid	Linezolid (Zyvox)	Vancomycin	
E. faecalis ATCC 29212	≤0.25	4	2	
E. faecalis A5962	1	32	8	
E. faecalis A7789	4	64	1	
E. faecium A5959	4	32	>128	
E. faecium A5960	4	64	>128	
E. faecium A8130	2	32	128	
E. faecium A9650	0.5	16	>128	
E. faecium A8948	≤0.25	8	>128	
E. faecium A9621	4	64	>128	

#### Viomycin binds between subunits, interacting with B2A bridge & tRNA



Viomycin, hygromycin & paromomycin bind to adjacent sites

